The Anti-seizure Medication Landscape and Their Effect on Non-seizure Symptoms
Neurology0.25 AMA PRA Category 1 Credit(s) ™
December 17, 2024
December 17, 2025
Primary Audience:
Epileptologists, adult and pediatric neurologists, and advanced practice providers (APPs), general neurologists, neuropsychologists
Relevant Terms:
Developmental and Epileptic Encephalopathies
Renée Shellhaas, MD, MS
Professor, Neurology
Division of Pediatric Neurology
Associate Dean, Faculty Promotions and Career Development
Washington University School of Medicine, St. Louis
Renée Shellhaas, MD, MS, is a Professor of Neurology and Senior Associate Dean for Faculty Promotions & Career Development at Washington University in St Louis School of Medicine, where she also holds the David T. Blasingame professorship. She received her MD from the University of Michigan and completed her residency in Pediatric Neurology and fellowship in Clinical Neurophysiology at the Children’s Hospital of Philadelphia. Following her fellowship, Dr. Shellhaas returned to the University of Michigan, where she joined the faculty and completed a Master’s Degree in Clinical Research Design and Statistical Analysis and the UM School of Public Health. She transitioned to a senior leadership position at Washington University in the fall of 2022.
Dr. Shellhaas’ research focuses on neonatal seizures and brain monitoring, sleep in at-risk infants, and early life epilepsy. Her work has been funded by NIH, PCORI, and multiple foundations. She has served on numerous CNS committees – including as Councilor for the MidWest – and is the 2024 Hower Award recipient.
Dr. Shellhaas is currently a member of the American Epilepsy Society Board of Directors. She is also a member of the American Academy of Pediatrics Section on Neurology Executive Committee, and serves as President of the Pediatric Epilepsy Research Foundation®.
Elaine C. Wirrell, M.D.
Professor, Neurology, Pediatrics
Division of Child and Adolescent Medicine
Director of Pediatric Epilepsy at Mayo Clinic
Dr. Elaine Wirrell is Professor of Neurology and Chair of Child Neurology at Mayo Clinic. She completed her MD degree at the University of British Columbia and her Neurology training at Dalhousie University. Her passion is to improve the lives of children with epilepsy, appreciating the tremendous impact this condition has on the entire family, and the critical importance of addressing seizures and comorbidities.
She was awarded the Mayo Clinic Distinguished Clinician award in 2016 and the Kiffin-Penry Award for Excellence in Epilepsy Care from the American Epilepsy Society in 2021. Dr. Wirrell is a founding member of the Pediatric Epilepsy Research Consortium, which was established to facilitate multicenter, collaborative research amongst US pediatric epileptologists with a focus on optimizing therapies and outcomes for young children with DEEs. She is Chair of the Medical Advisory Board of the Lennox-Gastaut Foundation and member of the Medical Advisory Board for the Dravet Syndrome Foundation.
Since 2019, Dr. Wirrell has served as Co-Editor-in-Chief for Epilepsy.com, the public education website for the Epilepsy Foundation of America, working to build pediatric content in key areas such as epilepsy syndromes, DEEs, genetic causes of epilepsy and comorbidities.
Through her work with the ILAE and the International Child Neurology Association, she has strived to improve epilepsy care world-wide. She is the past Co-Chair of the ILAE Nosology and Definitions Task Force, which proposed clinical criteria for defining epilepsy syndromes, and in her role as Chair of the Research Committee of ICNA, is developing resources to facilitate research in resource-limited regions.
She is a member of the ILAE Pediatrics Commission and current Co-Chair of the Medical Therapies Task Force. She is strongly committed to educating the next generation of child neurologists and pediatric epileptologists, serving as previous Program Director of Child Neurology at Mayo Clinic, and as prior Co-Chair of the Pellock Epilepsy Symposium for the past 6 years.
| 1. | ASSESS the emerging therapeutic benefits of newer ASMs in addressing NSS of DEE |
| 1. | ASSESS the emerging therapeutic benefits of newer ASMs in addressing NSS of DEE |
TITLE: The Anti-seizure Medication Landscape and Their Effect on Non-seizure Symptoms
Release Date: December 17, 2024
Expiration Date: December 17, 2025
STATEMENT OF NEED
There is a recognized need for enhanced understanding and application of personalized care strategies in the management of Developmental and Epileptic Encephalopathies (DEE). Current gaps include a lack of familiarity with the latest therapeutic options for addressing neuropsychiatric symptoms (NSS) associated with DEE and the need for more effective collaboration between healthcare providers, patients, and caregivers. This educational activity aims to bridge these gaps by providing up-to-date information and practical tools for personalizing treatment plans in DEE.
EDUCATIONAL OBJECTIVE
- ASSESS the emerging therapeutic benefits of newer ASMs in addressing NSS of DEE
TARGET AUDIENCE
This activity is designed for epileptologists, adult and pediatric neurologists, and advanced practice providers (APPs) working in both academic and community settings. The content is also relevant for general neurologists, neuropsychologists, and other healthcare professionals involved in the care of patients with DEE.
FACULTY
|
| Renée Shellhaas, MD, MS |
|
| Elaine C. Wirrell, M.D. |
CONTENT REVIEWER
Victor B. Hatcher, PhD
DISCLOSURE OF FINANCIAL RELATIONSHIPS
The “Policy on Identification, Mitigation, and Disclosure of Relevant Financial Relationships” of Albert Einstein College of Medicine-Montefiore Medical Center requires that any individual in control of content, including faculty, participating in CME activities disclose to the audience all relevant financial relationships with ineligible companies* in the past 24 months. Any individual in control of content who refuses to disclose, or whose disclosed relationships prove to create a conflict of interest, will be recused.
Individuals with the absence of relevant financial relationships with ineligible companies will be disclosed to the audience.
All financial relationships of individuals in a position to control the content of this CME activity are identified and mitigated prior to the educational activity.
*The ACCME defines an ineligible company as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
DISCLOSURE STATEMENT FOR PLANNERS, FACULTY, AND CONTENT REVIEWERS
The planners, and content reviewer for this educational activity have disclosed no relevant financial relationship(s) with an ACCME-defined ineligible company in the last 24 months.
FACULTY
Renée Shellhaas, MD, MS has no relevant financial relationships with ineligible companies within the past 24 months.
Elaine C. Wirrell, M.D. has no relevant financial relationships with ineligible companies within the past 24 months.
PROVIDERSHIP
This educational activity is jointly provided by Albert Einstein College of Medicine-Montefiore Medical Center and RealCME.
ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and RealCME, LLC. Albert Einstein College of Medicine-Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CREDIT DESIGNATION STATEMENT
Albert Einstein College of Medicine-Montefiore Medical Center designates this other activity (blended live and enduring curriculum) for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Credits
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.25 hours of Category 1 credit for completing this program.
DISCLOSURE OF UNLABELED USE
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a clinician relative to diagnostic and treatment options for a specific patient’s medical condition.
DISCLAIMER
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Albert Einstein College of Medicine-Montefiore Medical Center, RealCME or Jazz Pharmaceuticals. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
METHOD OF PARTICIPATION/INSTRUCTIONS ON HOW TO RECEIVE CREDIT
Estimated time to complete this activity: 15 minutes
This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed the post test and evaluation, and have received a digital copy of your credit certificate.
If you are seeking credit, you must complete the post test and evaluation at the conclusion of the activity. Your certificate can be printed immediately.
PRIVACY STATEMENT
Albert Einstein College of Medicine-Montefiore Medical Center, Center for Continuing Professional Development (Einstein-Montefiore) protects the privacy of personal and other information regarding participants and education collaborators. Einstein-Montefiore will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting to the ACCME. Einstein-Montefiore maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information collected from you.
COLLECTION AND USE OF YOUR PERSONAL INFORMATION
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing an activity. Required items include first name, last name, middle initial, degree, email address, address and phone number. These items are necessary. Participants are also required to complete an evaluation of each activity. All evaluative information submitted is collected, retained, and used by Einstein-Montefiore to continuously improve the learning experience. Einstein-Montefiore will not transfer, sell, or share personal information with outside parties or otherwise disclose personal information unless required to in a legal process. Einstein-Montefiore will retain your personal data only for the period necessary to accomplish the stated purposes and to comply with applicable laws.
CONTACT INFORMATION
For questions regarding CME credit, contact Albert Einstein College of Medicine-Montefiore Medical Center at cme@montefiore.org.
For technical questions related to this activity, please contact support@gathered.com.
ACKNOWLEDGEMENT OF FINANCIAL SUPPORT
This program is supported by an independent medical education grant from Jazz Pharmaceuticals.
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Microsoft Edge Google Chrome 60 or higher Mozilla Firefox 60 or higher Apple Safari 11.0 or higher For video, install the latest version of Quicktime. | Supported Phones & Tablets: iOS 9.3 and higher Android 7.0 (Nougat or higher) Microsoft Windows 8 Chrome OS |
| Additional Recommendations and Requirements | |
| Display Resolution & Color Depth | Resolution - 960 X 768 minimum - 1024 X 768 recommended min. Color Depth - 8 bits (256 colors) minimum - 16 bits (High colors) minimum |
| Audio | - Microphone - Speakers or headphones - Audio recording support |
| Word Processing | Software that can open, modify, and save documents in Rich Text Format (RTF). Microsoft Word and PowerPoint are recommended. |
